Melissa Bersanelli

Adjunct Professor in Medical Oncology

University of Parma

Italy

Research Interests

Explore related searches

Professors in Italy Professors in Immunology Immunology professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Melissa Bersanelli is an Adjunct Professor in Medical Oncology at the University of Parma, Italy. Her research focuses on the efficacy and biomarkers of immune checkpoint inhibitors in various cancers, particularly in geriatric patients and those with advanced melanoma and renal cell carcinoma. Recent publications include studies on the neutrophil-to-lymphocyte ratio as inflammation biomarkers, the impact of type 2 diabetes on treatment outcomes, and the role of influenza vaccination in patient survival.

Articles (11)

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Collaborators (20)

Ludimila Cavalcante

Associate Professor, Director, Sarcoma Medical Oncology, Associate Director, Developmental Therapeutics

University of Virginia

UNITED STATES

Melissa Bersanelli

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

Retrospective immunophenotypical evaluation of MET, PD-1/PD-L1, and mTOR pathways in primary tumors and pulmonary metastases of renal cell carcinoma: the RIVELATOR study addresses the issue of biomarkers heterogeneity

Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumab

Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup

Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study

Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a)

Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma

Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and Survival

Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade

Immune checkpoint inhibitors in adjuvant setting after radical resection of melanoma: a meta-analysis of the pivotal trials

Validation of a Novel Three-Dimensional (<i>3D Fusion</i>) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study

Collaborators (20)

Ludimila Cavalcante

Maurizio Colecchia

Marco Gaetano Tucci

Bruno Vincenzi

Umberto Basso

Giorgio Malpeli

Kazuma Sugimoto

Sebastiano Buti

maria rosaria raspollini

Yukari Uemura

Andrea Cossarizza

Valerio Gaetano Vellone

Maria Giuseppa Vitale

Filippo Alongi

Taketo Kawai

Stefano Gobbo

Holger Moch

Luisa Barzon

Yinghong Wang

Antonio D'Alessio

Make your next move.